FDA Long-Term Globalization Strategy Under Development
This article was originally published in The Gray Sheet
Executive Summary
Coping with an increasingly global device and drug industry will require a paradigm shift that relies less on FDA's own staff and more on data and resource sharing with other countries, the agency says.
You may also be interested in...
FDA Seeks Global Coalition To Share Regulatory Responsibilities
FDA will undertake a major, long-term effort to build a global coalition of regulators, key aims of which will be to systematically share information and collaborate on manufacturing inspections.
FDA Seeks Global Coalition To Share Regulatory Responsibilities
FDA will undertake a major, long-term effort to build a global coalition of regulators, key aims of which will be to systematically share information and collaborate on manufacturing inspections.
FDA Oversight Of Medical Products Remains A "High-Risk" Concern For GAO
The Government Accountability Office is once again listing FDA's ability to ensure the safety and effectiveness of devices, drugs and other medical products on its roster of "high-risk" concerns.